BAIJIN LIFE SCI (01466) announced that its indirect wholly-owned subsidiary, Beijing Baijin Biotechnology Co., Ltd. (Beijing Baijin), has entered into a strategic cooperation framework agreement with YouHuan (Suzhou) Biopharmaceutical Technology Co., Ltd. (YouHuan Bio). Under the agreement, Beijing Baijin will invest in YouHuan Bio by subscribing to its equity, aiming to establish a globally leading circular RNA (circRNA) technology research and development platform. This collaboration seeks to drive technological innovation in the field of cell therapy. The specific timing and amount of the investment have yet to be finalized.

The framework agreement will expire on December 31, 2026, and either party may terminate it with 10 days' prior notice.

YouHuan Bio is a biopharmaceutical company focused on circRNA technology platform development and innovative drug discovery, while also providing CRO (contract research organization) services. The company has successfully obtained U.S. patent authorization for its self-developed "Circular RNAs and Preparation Methods thereof" and a Chinese invention patent for "A Residue-Free Circular RNA Based on Ribozyme Self-Splicing and Its Preparation Method." Additionally, YouHuan Bio is engaged in deep collaborations with leading global pharmaceutical companies and has secured a contract with a multinational corporation in a specific cell application field.

In the initial phase of cooperation, the two parties will prioritize the following areas: 1. Exploring circRNA-based long-acting and stable expression of high-activity molecules such as cytokines and enzymes for treating liver metabolic diseases. 2. Research and development of circRNA combined with exosome drug-loading and cell drug-loading technologies to develop novel circRNA delivery systems leveraging Beijing Baijin’s exosome and cell platforms. 3. Developing engineered exosome and cell drugs with cardiovascular, cerebrovascular, and tissue repair capabilities for applications in emergency treatments (e.g., myocardial infarction, stroke), tissue regeneration, and neurological disorders such as Alzheimer's and Parkinson's. 4. Creating precise, efficient, and safe (integration-free) cell reprogramming and differentiation technologies for genetic disease therapies.